Loading patent…
AssigneeSanofi
InventorsPeter Adamson, Celine Amara, Alexandra Basset, Brigitte Demers, Dobrin Draganov, Paula Fraenkel, Kyle Jensen, Choi Siak-Leng, Delphine Valente, Samira Ziti-Ljajic
Estimating the term…
Provided herein are methods comprising multifunctional binding proteins comprising a first and a second antigen binding domain and all or part of an immunoglobulin Fc region or variant thereof, wherein the first antigen binding domain binds specifically to CD123 and the second antigen binding domain binds specifically to human NKp46, and wherein all or part of the immunoglobulin Fc region or variant thereof bind to a human Fc-γ receptor, for the treatment or prevention of leukemias and myelodysplastic disorders.
A method of treating or preventing a leukemia or a myelodysplastic syndrome in a subject in need thereof, the method comprising administering to the subject a binding protein comprising a first antigen binding domain with binding specificity to CD123 and a second antigen binding domain with binding specificity to NKp46, wherein the binding protein is administered to the subject at a dose of at least 3 μg/kg.
(canceled)
4-24. (canceled)
26-51. (canceled)
53-57. (canceled)
59-60. (canceled)
62-63. (canceled)
(canceled)
67-71. (canceled)
73-75. (canceled)
77-83. (canceled)
A method of treating or preventing a leukemia or a hematological neoplasm in a pediatric subject in need thereof, the method comprising administering to the subject a binding protein comprising a first antigen binding domain with binding specificity to CD123 and a second antigen binding domain with binding specificity to NKp46.
A method of treating or preventing blastic plasmacytoid dendritic cell neoplasm (BPDCN) in a subject in need thereof, the method comprising administering to the subject a binding protein comprising a first antigen binding domain with binding specificity to CD123 and a second antigen binding domain with binding specificity to NKp46.
88-92. (canceled)
94-99. (canceled)
101-102. (canceled)
104-105. (canceled)
(canceled)
109-113. (canceled)
115-118. (canceled)
120-141. (canceled)
Dependencies are inferred from the claim text.